Piedmont Plus Innovation
$24.7K 250 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
IBA Proton Therapy, Inc.
IBA Proton Therapy, Inc. reported $24,595.73 across General Payments, Research, and Ownership to 40 physicians and teaching hospitals across 40 transactions.
- $24.6K Below-median payer
- All-tracks total
- 40 Below-median volume
- Transactions
- 40 Below-median reach
- Recipients
- −$25.0K
- General Payments vs PY2023
IBA Proton Therapy, Inc. reported $24,595.73 across all CMS Open Payments tracks (General + Research + Ownership) to 40 physicians and teaching hospitals in Program Year 2024 - ranking #1499 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $24,595.73, averaging $614.89 per recipient.
IBA Proton Therapy, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer iba-proton-therapy-inc IBA Proton Therapy, Inc.
$24.6K · #1499/1,925 · 0.0% industry · PY2024
- TOT $24.6K
- RANK #1499
- SHARE 0.0%
- TXN 40
- RCP 40
- CAT 3
- GEN $24.6K
- ΔGEN −$25.0K
- TOP1 8.8%
- PY 2024
Volume peers
Nearest volume peer: Piedmont Plus Innovation ($24.7K)
IBA Proton Therapy, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
IBA Proton Therapy, Inc.'s CMS-reported General Payments decreased by $25.0K (−50.4%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: IBA PROTON THERAPY, INC.PY2023: IBA PROTON THERAPY, INC.PY2024: IBA Proton Therapy, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $49,629.49
- PY2024
- $24,595.73
What the Data Shows for IBA Proton Therapy, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For IBA Proton Therapy, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Food and Beverage" leads the 3-category general-payment breakdown below at $19.7K (80.0% of General Payments, 37 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 3 types of general payments, IBA Proton Therapy, Inc.'s largest category was "Food and Beverage" at $19.7K - 80.0% of General Payments.
How IBA Proton Therapy, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $19.7K | 37 | 80.0% |
| Honoraria | $2.9K | 2 | 11.9% |
| Consulting Fee | $2.0K | 1 | 8.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $9,752.02 (39.6%) of $24,595.73 in this company's General Payments records across 35 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for IBA Proton Therapy, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Ramesh Rengan
$2,175.58 across 1 reported transactions
- 2
Jing Zeng
$2,071.38 across 1 reported transactions
- 3
University Of Kansas Hospital
$2,000.00 across 1 reported transactions
- 4
Alonso Gutierrez
$1,860.59 across 1 reported transactions
- 5
Charles Simone
$1,644.47 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
IBA Proton Therapy, Inc.'s spend rank (#1499 of 1,925, bottom 22% by spend) and concentration rank (#1,264 of 1,838, bottom 31% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- iotaMotion, Inc. : $37.4K total payments, HHI 552
- Lightforce Orthodontics, Inc. : $511.3K total payments, HHI 551
- DENTSPLY IH Inc. : $389.9K total payments, HHI 550
- Chugai Pharmaceutical Co., Ltd. : $494.0K total payments, HHI 550
- Novocure Inc. : $1.2M total payments, HHI 549
- Blue Surgical Llc : $12.0K total payments, HHI 549
- IBA Proton Therapy, Inc. (this company) : $24.6K total payments, HHI 548
- Rattan And Associates : $17.3K total payments, HHI 548
- Apellis Pharmaceuticals, Inc. : $3.5M total payments, HHI 546
- Abanza Inc. : $3.5K total payments, HHI 546
- Pajunk Medical Systems, LP : $4.4K total payments, HHI 538
- Cagent Vascular INC : $103.5K total payments, HHI 534
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as IBA Proton Therapy, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about IBA Proton Therapy, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with IBA Proton Therapy, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Forthright Medical-AZ, LLC
$24.7K 251 recipients
Compare payment profiles
Helsinn Therapeutics (U.S.), Inc.
$24.3K 481 recipients
Compare payment profiles
Biocodex, Inc.
$25.0K 333 recipients
Compare payment profiles
CIVCO Medical Instruments
$25.0K 395 recipients
Compare payment profiles
BioWound Solutions, Inc.
$24.1K 124 recipients
Compare payment profiles
Put this to use
IBA Proton Therapy, Inc. ranks #1499 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just IBA Proton Therapy, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.